ZebiAI Joins the EUbOPEN Consortium to Provide Tools to Unlock Disease Biology

We are delighted to to welcome ZebiAI as a new partner in EUbOPEN. ZebiAI Therapeutics is focused on applying machine learning at all stages of small molecule drug discovery to accelerate target validation and advance new therapeutics for unmet medical needs. We wish the ZebiAI team a warm welcome and strongly believe that access to DNA-encoded screening and artificial intelligence (AI) technology could have a huge impact on our chemical probe programme and the technology section. Click here for the ZebiAI press release. 

You can find out more on ZebiAI technology by visiting their webite www.zebiai.com  or head to Twitter @zebi_ai


ZebiAI Logo